The metastatic capacity of rat mammary tumors induced with N-nitrosomethyl urea was tested in BUF/N inbred female rats by successive transplantation. After the first and second passage, tumor cells appeared diffusely distributed throughout the bone marrow and spleen, confirming results reported by others; no other metastases were observed. After six successive transplantations, large, well-defined tumor nodules were observed in the liver, spleen, lung, and the peritoneal surface of the intestines in 40% of the injected animals. The morphology of the primary and metastatic tumors was compared by light microscopy. The tumors appeared to be adenocarcinomas with differing degrees of differentiation. No morphological differences could be observed between the primary and the metastatic tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.2930180104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Functional Breast Imaging: A sCMOS Camera-Based Lock-in Implementation for Dynamic Tomography.
J Biophotonics
January 2025
The College of Precision Instrument and Optoelectronics Engineering, Tianjin University, Tianjin, China.
Diffuse optical tomography (DOT) enables the in vivo quantification of tissue chromophores, specifically the discernment of oxy- and deoxy-hemoglobin (HbO and HbR, correspondingly). This specific criterion is useful in detecting and predicting early-stage neoadjuvant breast cancer treatment response. To address the issues of the limited channels in the fiber-dependent breast DOT system and limited signal-to-noise ratio in the camera-dependent systems, we hereby present a camera-based lock-in detection scheme to achieve dynamic DOT with improved SNR, which adopted orthogonal frequency division multiplexing technology.
View Article and Find Full Text PDFAge, cancer, and the dual burden of cancer and doxorubicin in skeletal muscle wasting in female rats: which one to blame?
Biogerontology
January 2025
UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116, Gandra, Portugal.
Sarcopenia and cancer cachexia are two life-threatening conditions often misdiagnosed. The skeletal muscle is one of the organs most adversely affected by these conditions, culminating in poor quality of life and premature mortality. In addition, it has been suggested that chemotherapeutic agents exacerbate cancer cachexia, as is the case of doxorubicin.
View Article and Find Full Text PDFCharacterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant.
Sci Rep
January 2025
Division of Hematology and Oncology, University of California, 1450 3rd Street, San Francisco, CA, 94143, USA.
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting implant placed within the breast would provide the risk reduction benefit of hormonal therapy, but without the adverse effects that limit compliance. To this end, we demonstrate that when placed adjacent to mammary tissue in the 7,12-dimethylbenz[a]anthracene-induced rat breast cancer model a fulvestrant-eluting implant delays breast cancer with minimal systemic exposure.
View Article and Find Full Text PDFDual ligand functionalized pH-sensitive liposomes for metastatic breast cancer treatment: and assessment.
J Mater Chem B
January 2025
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, 226025, India.
This research demonstrates the design and development of a novel dual-targeting, pH-sensitive liposomal (pSL) formulation of 5-Fluorouracil (5-FU), , (5-FU-iRGD-FA-pSL) to manage breast cancer (BC). The motivation to explore this formulation is to overcome the challenges of systemic toxicity and non-specific targeting of 5-FU, a conventional chemotherapeutic agent. The proposed formulation also combines folic acid (FA) and iRGD peptides as targeting ligands to enhance tumor cell specificity and penetration, while the pH-sensitive liposomes ensure the controlled drug release in the acidic tumor microenvironment.
View Article and Find Full Text PDFHumanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity.
Acta Pharmacol Sin
January 2025
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Cancer heterogeneity, characterized by diverse populations of tumorigenic cells, involves the occurrence of differential phenotypes with variable expressions of receptor tyrosine kinases. Aberrant expressions of mesenchymal-epithelial transition (MET) and recepteur d'origine nantais (RON) receptors contribute to the phenotypic heterogeneity of cancer cells, which poses a major therapeutic challenge. This study aims to develop a dual-targeting antibody-drug conjugate (ADC) that can act against both MET and RON for treating cancers with high phenotypic heterogeneity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!